UnknownPhase 1

Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO

France238 participantsStarted 2023-09-18

Plain-language summary

This multicenter randomized controlled trial compare two transfusion strategies of red blood cells transfusion in patients supported by veno-arterial extracorporeal membrane oxygenation for refractory cardiogenic shock. An individualized transfusion strategy based on ScVO2 level, is compared to a conventionnal strategy based on predefined hemoglobin threshold. The primary endpoint is the consumption of packed red blod cells, secondary endpoints are subgroup analysis, mortality, morbidity, and cost-effectiveness

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age of 18 and older, * supported by peripheral VA-ECMO * for cardiogenic shock * Life expentency \>90 days * Central venous line available ScVO2 measurement Exclusion Criteria: * Pregnancy, * Lack of health insurance, * Opposition to blood transfusion, * Known congenital hemoglobin disease or disorder, * Metabolic alcaloosis with pH\>7.8, * eCPR, * Legally incapacitated adults

What they're measuring

Number of PRBCs transfused per VA-ECMO day of support

Timeframe: From randomisation until VA-ECMO weanning assessed up to 28 days

Trial details

NCT IDNCT05699005

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-18

Contact for this trial

Mouhamed MOUSSA, MD

0320445962 mouhamed.moussa@chru-lille.fr

View on ClinicalTrials.gov More Cardiogenic Shock trials